Celadon Pharmaceuticals Plc (CEL.L)
GBp 7.0
(7.69%)
GBp 7.0
(7.69%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -6.39 Million GBP | 54.32% |
| 2022 | -13.61 Million GBP | -419.59% |
| 2021 | -2.39 Million GBP | -327.66% |
| 2020 | -660.24 Thousand GBP | -437.0% |
| 2019 | -191.32 Thousand GBP | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.02 Million GBP | 17.94% |
| 2024 Q2 | -1.02 Million GBP | 0.0% |
| 2023 Q2 | -3.34 Million GBP | -100.0% |
| 2023 FY | - GBP | 54.32% |
| 2023 Q3 | -1.24 Million GBP | 62.71% |
| 2023 Q1 | -1.67 Million GBP | 51.77% |
| 2023 Q4 | -1.24 Million GBP | 0.0% |
| 2022 Q2 | -8.98 Million GBP | -100.02% |
| 2022 Q1 | -4.48 Million GBP | -486.99% |
| 2022 FY | - GBP | -419.59% |
| 2022 Q4 | -3.47 Million GBP | -92.3% |
| 2022 Q3 | -1.8 Million GBP | 79.9% |
| 2021 FY | - GBP | -327.66% |
| 2021 Q2 | -482.17 Thousand GBP | -279.75% |
| 2021 Q4 | -764.82 Thousand GBP | 0.0% |
| 2021 Q1 | -126.97 Thousand GBP | 33.59% |
| 2021 Q3 | -764.82 Thousand GBP | -58.62% |
| 2020 Q4 | -191.19 Thousand GBP | -115.68% |
| 2020 Q2 | -120.55 Thousand GBP | -23.14% |
| 2020 Q1 | -97.9 Thousand GBP | 0.0% |
| 2020 FY | - GBP | -437.0% |
| 2020 Q3 | -88.65 Thousand GBP | 26.46% |
| 2019 Q3 | -88.59 Thousand GBP | 0.0% |
| 2019 FY | - GBP | 0.0% |
| 2019 Q1 | -77.95 Thousand GBP | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|